Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPPCG in Metastatic Pancreatic Cancer
NCT02754726Phase 2Completed
- Sponsor
- HonorHealth Research Institute
- Start
- Apr 2016
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and paricalcitol in pancreatic adenocarcinoma (PDAC), sponsored by HonorHealth Research Institute. Primary endpoint: Complete Response Rate up to 84 months. Started Apr 2016; status: completed.
02
Drugs
nivolumabparicalcitol
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02754726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754726.